<DOC>
	<DOCNO>NCT00368186</DOCNO>
	<brief_summary>The primary objective study assess immunogenicity tolerance heptavalent pneumococcal conjugate vaccine ( Prevenar ) young infant ( 2 month age ) sickle cell disease administred 2,3 , 4 month age .</brief_summary>
	<brief_title>Immunogenicity Safety Study Pneumococcal 7-Valent Conjugate Vaccine Sickle Cell Disease Infants .</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion Criteria Infants neonatal diagnosis sickle cell disease confirm hemoglobin status hemoglobin electrophoresis . Exclusion Criteria Previous immunization pneumococcalcontaining vaccine . History pneumococcal invasive disease ( meningitis , bacteremia , pneumonia ) . Known suspected impairment immune system ( include HIV infection ) recipients immunosuppressant agent . Other Exclusions apply .</criteria>
	<gender>All</gender>
	<minimum_age>57 Days</minimum_age>
	<maximum_age>112 Days</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>